Infection Control for Safe Environments

SteriLumen was founded in 2016 to provide novel, easy to deploy and effective devices to protect vulnerable populations from dangerous infections.

Our engineers create patented products that manage infection control for safe environments. We employ proven germicidal UVC in a variety of automated and connected designs, rising to meet the disinfection challenges in our most important industries.

Our guiding principle is to create safe environments without emission of ozone or other chemicals, and provide the modern convenience of connected, remote asset management capabilities that enable Data Driven Disinfection™.

In February 2021 we acquired Akida LLC, makers of the Airocide™ product line which was developed with NASA to address air-borne pathogens and bring market-leading air purification technology to the fight against coronavirus. Together, our advanced designs and infection control for safe environment technologies significantly lower the risk of  infection, controlling outbreaks and allowing businesses to get back to what they do best. We are a wholly owned subsidiary of Applied UV Inc. (NASDAQ:AUVI).

Team

Q Saeed

Q Saeed

Chief Executive Officer

Mr. Saeed has over 25 years of proven experience in strategic planning, operations, sales and executive management of advanced technologies.
Full Bio

A seasoned CEO and senior executive with a record of achievement in sales, marketing and operations development, strategic planning, and business development. Mr. Saeed recently was CEO of Ubiquity LLC and advised the National Mental Health Innovation Center (NMHIC), worked with CU Innovations on business partnerships and co development with their technology innovation network (TIN) on virtual and augmented reality to conduct interventions and training protocols at the University of Colorado Anschutz Medical Center.

Previously, in 2016 he was founder and CEO of Vital Neuro, Inc. which has converged machine learning and cloud technologies in a closed feedback system. Vital Neuro is an evidence based, proven service relieving employee stress with a personalized 15 minute daily sessions through an connected app.

Prior to that and until the end of 2015 Mr. Saeed spent three and a half years at Kymeta Corporation, a Bill Gates company, as the EVP of strategy and development creating a market approach to the connected car strategy, sourcing and securing unique raw materials and industry relations and partnerships.

Among several smaller startups, Mr. Saeed Co-founded Open Range Communications in 2004 to deliver broadband to rural and underserved communities in the US. In 2001 Mr. Saeed was instrumental in the launch of the first cellular Blackberry at T-Mobile USA where he was part of the pioneering team introducing the first device converging voice and data to the market in 2001. He worked at AT&T wireless advanced services organization introducing CDPD and converged wireless data through 1999.

James Doyle

James Doyle

Chief Operating Officer

Mr. Doyle has over 28 years’ experience in general management, operations, marketing, sales and consulting.

Full Bio

Most recently, Mr. Doyle was the President of Panasonic Enterprise Solutions company, a $450 million solution and engineering company focused primarily on North America, but with limited clients in Asia and Europe. This company built complex solutions for Panasonic’s global customers in sports and entertainment, energy, and smart city industries. His clients ranged from the Philadelphia Eagles to MGM to the US Government.

Before joining Panasonic, Mr. Doyle was a Consulting Partner with IBM Global Business Services leading its North American Electronics industry solutions unit, the final role in a thirteen-year span with IBM.

Mr. Doyle currently serves on the board of Mobilitynext, a nonprofit organization that brings public and private entities together to solve the world’s most challenging transportation and mobility challenges.

Mr. Doyle also served as an Officer in the US Marine Corps, participating in Operation Restore Hope in Somalia. Mr. Doyle has an MBA in Marketing and Decision & Information Systems from Indiana University and a BS in Marketing from Syracuse University.

Rhonda Wallen

Rhonda Wallen

Vice President, Marketing & Corporate Development

Ms. Wallen’s track record in life sciences spans over 20 years with leadership roles in both large multinationals and start-up companies.

Full Bio

She was most recently head of Corporate Development at Terumo BCT, the $1 billion biomedical division of Terumo Corporation (4543.T-JP:TokyoSE), with responsibility for partnerships to augment the division’s products and technologies for life-saving blood and cell-based therapies.

Previously she served as Chief Operating Officer of Andarix Pharmaceuticals, a clinical stage oncology therapeutics company, and President/CEO of Caveo Therapeutics, a biotechnology company with reagent and therapeutic antibody product lines. In consulting roles with Cygnet Venture Management, she served as interim management for senior level business development and marketing functions, working with life science CEOs and founders and helping clients raise over $30M.

Ms. Wallen was formerly an investment professional with Sequel Venture Partners and is a Director of Ekso Bionics (Nasdaq: EKSO), and Boulder Community Health.

Robert Berger

Robert Berger

Vice President, Global Sales

Mr. Berger most recently served as vice president of strategy and go-to-market at Zivaro, Inc., a provider of consulting and technology services, where he successfully refactored the analytics business and delivered significant revenue growth and margin expansion.

Full Bio

During his tenure at Zivaro, Mr. Berger’s sales performance and related strategic initiatives were recognized with awards for Manager of the Year, Enterprise Sales Team of the Year, Community Volunteer of the Year and Presidents Club.

Prior to Zivaro, Mr. Berger was a Managing Director at Hughes Cloud Services, where he was recruited by the president to build the business plan, go-to-market strategy, and branding with overall responsibility for sales, marketing, partner, product, and corporate development. Before joining Hughes Cloud Services, he served in executive sales leadership roles for numerous companies, including Credera Inc., Viawest, Inc. and T-Mobile USA.

Mr. Berger was a past Board Chair Associate Board of Directors for Big Brothers Big Sisters of Colorado and has served on numerous steering committees of the Colorado Technology Association. He is a graduate of the University of Colorado, Boulder and holds a bachelor’s degree in International Affairs.

Board of Directors

Applied UV Inc.

Joel Kanter

Joel Kanter

Chairman

Mr. Kanter serves as President of Windy City, Inc., a privately held investment firm, since July 1986.
Full Bio
Walnut Financial’s primary business focus was the provision of various forms of financing to small business including equity financing to start-up and early stage development companies, bridge financing to small and medium-sized companies, and later stage institutional financing to mature enterprises. Tower Hill Capital bought the Company in 1999 in a transaction valued at approximately $400 million. From 1978 – 1980, Mr. Kanter served as a Legislative Assistant to former Congressman Abner J. Mikva (D-Ill.). In that position, Mr. Kanter provided support to Congressman Mikva with respect to activities related to his position on the House Judiciary Committee. In particular, Mr. Kanter was intimately involved in efforts to reform the Federal Criminal Code. Mikva subsequently became the Chief Judge of the U.S. Court of Appeals for the District of Columbia Circuit, and then served as White House Counsel to President Clinton. From 1980 – 1983, Mr. Kanter served as Special Assistant to the National Association of Attorneys General. In that position, he represented the interests of the State Attorneys General in Washington, D.C. in the criminal justice and environmental arenas. Mr. Kanter serves on the Board of Directors of one currently public company, Magna-Labs, Inc., which was formerly involved in the development of a cardiac MRI device. Mr. Kanter also serves on the boards of several private biotechnology companies. Mr. Kanter is a National Association of Corporate Directors “Governance Fellow.” Mr. Kanter is a current Trustee Emeritus and past President of the Board of Trustees of The Langley School in McLean, Virginia, a former Trustee at the Georgetown Day School in Washington, D.C., and a former Trustee of the Union Institute & University, the Country’s first Online University.
Dr. Eugene A. Bauer

Dr. Eugene A. Bauer

Director

In 2010, Dr. Bauer co-founded Dermira, a publicly traded specialty biopharmaceutical company acquired by Eli Lilly and Company in 2020.

Full Bio
Dr. Bauer served as Chief Medical Officer of Dermira, a wholly-owned subsidiary of Lilly, through March 2020. Prior to founding Dermira, Dr. Bauer served as Director, President and Chief Medical Officer of Pelpin, Inc., a publicly traded specialty pharmaceutical company, from 2008 to 2010. Dr. Bauer served as Chief Executive Officer of Neosil, Inc., a specialty pharmaceutical company, from 2004 to 2008, and he co-founded and served as a member of the board of directors at Connetics, a publicly traded specialty pharmaceutical company, from 1990 to 2006. Prior to initiating his career in industry, Dr. Bauer served as Dean of Stanford University School of Medicine from 1995 to 2001 and as Chair of the Department of Dermatology at Stanford University School of Medicine from 1988 to 1995. Dr. Bauer is Professor Emeritus at Stanford University School of Medicine, a position he has held since 2002. Dr. Bauer was a U.S. National Institutes of Health (“NIH”)-funded investigator for 25 years and has served on review groups and Councils for the NIH. Dr. Bauer has served on the boards of directors of a number of public and private companies, including Aevi Genomic Medicine, Inc. (formerly Medgenics, Inc.), First Wave Technologies, Inc., and Kadmon Holdings, Inc. He is member of numerous honorific societies, including the National Academy of Medicine. Dr. Bauer received his B.S. in medicine from Northwestern University and his M.D. from Northwestern University Medical School.
Alastair J. Clemow, Ph.D.

Alastair J. Clemow, Ph.D.

Director

Dr. Clemow currently serves as Chairman of Ensemble Orthopedics, an early-stage company developing an innovative pyrocarbon finger joint for the treatment for early state osteoarthritis.

Full Bio
From 2010 to 2019, Dr. Clemow served as President and Chief Executive Officer of Regentis Biomaterials, a private company developing an innovative material for cartilage repair. He also held positions of president and chief executive officer in a number of companies that he helped found, including Nexgen Spine, Inc., which developed an artificial spinal disc; Gelifex, Inc., which developed an innovative spinal nucleus replacement implant and which was acquired in 2004 by Synthes Spine, Inc.; and Minimally Invasive Surgical Technologies, Inc., which developed a novel series of implants for minimally invasive total knee replacement and which was acquired in 2005 by MAKO Surgical Corp. From 2000 to 2004, Dr. Clemow served as Principal of Tanton Technologies, Inc., an organization that provided strategic and technical assessment of new medical device opportunities for large, mid-cap, and early-stage development companies. From 1981 to 2000, Dr. Clemow held numerous positions with Johnson & Johnson, including Vice President of Worldwide Business Development for Ethicon Endo-Surgery, Inc.; Vice President of New Business Development for Johnson & Johnson Professional, Inc.; and Director of Research and Development of Johnson & Johnson Orthopedics. In those capacities, Dr. Clemow was responsible for acquiring or developing what today represents billions of dollars of Johnson & Johnson revenue. Dr. Clemow serves or has served on the boards of numerous private and public companies including Aevi Genomics; Encore Medical; Echo Healthcare Acquisition Corp.; BioMedical Enterprises, Inc.; and Kinetic Muscles, Inc. He graduated from the University of Surrey with a Bachelor of Science Degree in metallurgy and Ph.D. in metallurgy and earned his MBA degree from Columbia University in New York.
Dallas C. Hack, M.D., M.P.H.

Dallas C. Hack, M.D., M.P.H.

Director

Dr. Hack is board certified in General Preventive Medicine and Public Health, and a Fellow in the American College of Military Public Health.

Full Bio
He directed trauma research for the military from 2008 to 2014, with responsibility for more than $2 billion in grant funding. He served as Command Surgeon at the strategic level during Operations Enduring Freedom and Iraqi Freedom. He held numerous military medical leadership positions including Commander of the NATO Headquarters Healthcare Facility, and Command Surgeon at the strategic level during Operations Enduring Freedom and Iraqi Freedom. COL(R) Hack received numerous military awards including the Bronze Star, two Legion of Merit awards, and was inducted as a Distinguished Member of the Military Order of Medical Merit. He has a BA from Andrews University (1972), an MPH from Johns Hopkins University (1995), a MD from Loma Linda University (1976), an MSS from the US Army War College (2004), and a CPE from the Certifying Commission in Medical Management (1997). He was recognized as the Distinguished Alumnus of the Year by Loma Linda University in May 2015. Dr. Hack has an appointment from the School of Medicine, University of Pittsburgh as Adjunct Professor of Neurosurgery and from Virginia Commonwealth University as an Associate Clinical Professor, Department of Physical Medicine and Rehabilitation. After retiring from 28 years of military service in 2015, Dr. Hack has worked with numerous biotechs and non-profits to advance medical research and transition the progress to improved clinical practice.
Eugene E. Burleson

Eugene E. Burleson

Director

Mr. Burleson is a private investor. He served as Chairman of PET DRx Corporation from June 2005 to July 1, 2010, and its Chief Executive Officer from October 2008 until its acquisition by VCA Antech in July 2010.

Full Bio
Mr. Burleson was a director of HealthMont Inc. from September 2000 until its acquisition by SunLink in October 2003. Mr. Burleson served as Chairman of the Board of Directors of Mariner Post-Acute Network, Inc. from January 2000 to June 2002. Mr. Burleson also served as Chairman of the Board of Directors of Alterra Healthcare Inc. a developer and operator of assisted living facilities and is on the Board of Deckers Outdoor Corporation Inc. Mr. Burleson served as Chairman of the Board of GranCare Inc. from October 1989 to November 1997. Additionally, Mr. Burleson served as President and Chief Executive Officer of GranCare Inc. from December 1990 to February 1997. Upon completion of the merger of GranCare’s pharmacy operations with Vitalink Pharmacy Services Inc. in February 1997, he became Chief Executive Officer and a Director of Vitalink Pharmacy Services Inc. Mr. Burleson resigned as Chief Executive Officer and Director of Vitalink Pharmacy Services in August 1997. From June 1986 to March 1989, Mr. Burleson served as President, Chief Operating Officer and a Director of American Medical International Inc. (“AMI”), an owner and operator of acute care hospitals. Based in London from May 1981 to June 1986, Mr. Burleson served as Managing Director of AMI’s international operations. Mr. Burleson received his early management training at Eastman Kodak from 1963 to 1974. He graduated from East Tennessee State University with a Bachelor of Science Degree in accounting and earned an MBA degree in 1972.